CompletedPhase 4NCT01815138

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UConn Health
Principal Investigator: Lawrence Engmann, MD
UConn Health
Intervention: hCG(drug)
Enrollment: 89 enrolled
Eligibility: 18-39 years · FEMALE
Timeline: 2013 – 2016

Study locations (1)

University of Connecticut Health Center, Farmington, Connecticut, United States

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01815138 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials